Korenberg Matthew E
SEC CIK 1649903 · EDGAR
BoughtSold
Most active insiders at PVLA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Goin Kathleen | COO | — | $5.51M |
| 2 | JENKINS GEORGE M | Dir | $550.0K | $4.17M |
| 3 | HERON ELAINE J | Dir | $300.0K | — |
| 4 | KIRITSY CHRISTOPHER P | Dir | — | $49.1K |
| 5 | Korenberg Matthew E | CFO, Treas | — | — |
Transactions 29
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-16 16:05 | 2026-06-12 | PVLA | PALVELLA THERAPEUTICS, INC. | Korenberg Matthew E | CFO, Treas | M - OptEx | $13.60 | +1,000 | 1,000 | New | +$13.6K |
| 2026-06-05 16:46 | 2026-06-04 | LFCR | LIFECORE BIOMEDICAL, INC. DE | Korenberg Matthew E | Dir | A - Grant | — | +25.9K | 70.0K | +59% | — | |
| 2025-07-17 | 2025-07-15 | LFCR | LIFECORE BIOMEDICAL, INC. DE | Korenberg Matthew E | Dir | A - Grant | — | +19.5K | 44.1K | +79% | — | |
| DM | 2024-09-24 | 2024-09-20+ | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | M - OptEx | $51.80 | +14.8K | 57.1K | +35% | +$764.3K |
| DM | 2024-09-24 | 2024-09-20+ | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | S - Sale+OE | $102.35 | -16.0K | 50.8K | -24% | -$1.64M |
| DM | 2024-09-18 | 2024-09-16 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | M - OptEx | $58.49 | +5,774 | 51.0K | +13% | +$337.7K |
| DM | 2024-09-18 | 2024-09-16 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | F - Tax | $105.00 | -3,214 | 49.9K | -6% | -$337.5K |
| M | 2024-08-26 | 2024-08-22+ | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | S - Sale | $105.34 | -18.9K | 67.2K | -22% | -$1.99M |
| 2024-08-21 | 2024-08-19 | LFCR | LIFECORE BIOMEDICAL, INC. DE | Korenberg Matthew E | Dir | A - Grant | — | +24.6K | 24.6K | New | — | |
| 2024-08-13 | 2024-08-09 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | S - Sale | $98.50 | -18.2K | 68.4K | -21% | -$1.80M | |
| 2024-07-02 | 2024-06-28 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, Chief Operating | J - Other | $60.71 | +350 | 86.6K | +0.4% | +$21.2K | |
| M | 2024-05-15 | 2024-05-13+ | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, Chief Operating | S - Sale | $84.99 | -17.6K | 100.4K | -15% | -$1.50M |
| D | 2024-02-29 | 2024-02-27 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, CHIEF OPERATING | A - Grant | $0.00 | +14.4K | 103.9K | +16% | $0 |
| 2024-02-16 | 2024-02-15 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, CHIEF OPERATING | F - Tax | $74.65 | -4,778 | 89.4K | -5% | -$356.7K | |
| 2024-01-04 | 2024-01-02 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, CHIEF OPERATING | F - Tax | $72.31 | -2,917 | 94.2K | -3% | -$210.9K | |
| 2023-12-06 | 2023-12-05 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, CHIEF OPERATING | F - Tax | $59.61 | -1,984 | 97.1K | -2% | -$118.3K | |
| 2023-07-10 | 2023-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, CHIEF OPERATING | J - Other | $56.78 | +376 | 99.1K | +0.4% | +$21.3K | |
| D | 2023-02-27 | 2023-02-23 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | A - Grant | $0.00 | +9,069 | 98.7K | +10% | $0 |
| 2023-02-17 | 2023-02-15 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | F - Tax | $72.98 | -2,890 | 89.7K | -3% | -$210.9K | |
| 2022-12-30 | 2022-12-28 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | F - Tax | $66.29 | -3,859 | 92.6K | -4% | -$255.8K | |
| D | 2022-12-15 | 2022-12-13 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | A - Grant | $0.00 | +14.0K | 96.4K | +17% | $0 |
| 2022-12-01 | 2022-11-30 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | F - Tax | $72.90 | -3,593 | 82.4K | -4% | -$261.9K | |
| 2022-11-03 | 2022-11-01 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | Pres, COO | A - Grant | $0.00 | +27.7K | 86.0K | +48% | $0 | |
| 2022-07-06 | 2022-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | EVP, CFO, Fin, Strategy | J - Other | $75.84 | +164 | 52.5K | +0.3% | +$12.4K | |
| 2022-06-14 | 2022-06-10 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | EVP, CFO, Fin, Strategy | A - Grant | $0.00 | +8,062 | 52.4K | +18% | $0 | |
| M | 2022-02-16 | 2022-02-15 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | EVP, CFO, Fin, Strategy | F - Tax | $123.68 | -3,407 | 46.8K | -7% | -$421.4K |
| M | 2022-01-28 | 2022-01-26 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | EVP, CFO, Fin, Strategy | A - Grant | $0.00 | +11.7K | 51.3K | +29% | $0 |
| M | 2022-01-28 | 2022-01-26 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | EVP, CFO, Fin, Strategy | F - Tax | $113.68 | -3,628 | 47.7K | -7% | -$412.4K |
| 2021-07-02 | 2021-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E | EVP, CFO, Fin, Strategy | J - Other | $85.91 | +247 | 39.7K | +0.6% | +$21.2K |
Purchase Sale Sale after option exercise All abbreviations